Quest Diagnostics Incorporated is buying cancer-detection company Haystack Oncology for $300m in cash with plans to launch their liquid biopsy test in 2024, the companies announced on 27 April.
Baltimore-based Haystack Oncolgy, whose liquid biopsy technology is based on research from renowned Johns Hopkins University oncologists Bert Vogelstein, Ken Kinzler and Nickolas
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?